1. Scrip
  2. >>Leadership
  3. >>Executives On The Move

Novartis CEO-Designate Set To Bring More Automation To Drug Discovery

 
• By Sten Stovall

Vasant Narasimhan, who is replacing Joseph Jimenez as Novartis' CEO next year, is an advocate of automation and artificial intelligence in future drug discovery.

Relay
Novartis CEO Joe Jimenez Will Hand Over To Vas Narasimhan On Feb 1, 2018 • Source: Shutterstock

With Novartis AG's root-to-branch revamp a reality, its American CEO Joseph Jimenez is passing the leadership baton to the Swiss group's chief medical officer Vasant Narasimhan – another American who has been increasingly at the center of its drug development and commercialization strategy and who is a big proponent of automation and artificial intelligence in future discovery.

News of Jimenez's departure - effective Feb. 1, 2018 - came as a surprise to the industry, and comes after eight years at the helm of Europe’s biggest medicine maker, during which time he restructured the Swiss group with asset swaps and prepared the sale of underperforming divisions

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Executives On The Move

Executives On The Move: Pathos Procures CEO From AstraZeneca, New CEO For TME Pharma, And More

Recent moves in the industry include changes at the top at Akamis Bio, Innospera Pharma & Ispen, plus Astellas Korea appoints an ex-Novartis Korea executive.

Executives On The Move: Altesa BioSciences Acquires Chief Medical Officer From GSK, Scholar Rock Gets A New CEO, And More

Recent moves in the industry include C-suite changes at Scholar Rock and Augustine Therapeutics, plus Contineum Therapeutics acquires chief medical officer from Gilead Sciences.

Executives On The Move: Five CEOs, Three CFOs And Two CMOs Among This Week’s Changes

Recent moves in the industry include changes at the top at Immunovant, Zymeworks and Cassava Sciences, among others, plus Zealand Pharma acquires chief scientific officer from Eli Lilly.

Executives On The Move: Ten CMOs And Three CEOs and CFOs Each Among This Week’s Changes

Recent moves in the industry include C-suite changes at Dyne Therapeutics, City Therapeutics and ProQR Therapeutics, plus Madrigal Pharmaceuticals acquires chief medical officer from Novartis.

More from Leadership